-
The Serum Institute of India CEO's comments follow recent Mahindra Group Chairman Anand Mahindra's remarks saying that it's not about working 48, 70, or 90 hours a week but rather the output produced
-
Adar Poonawalla's Serene Productions recently acquired a 50% stake in Karan Johar’s Dharma Productions and Dharmatic Entertainment, sparking a strong reaction from internet users. This strategic partnership aims to create compelling content for a global audience, with Johar continuing as Executive Chairman to steer the company's creative vision.
-
This comes in the light of the dirty standoff between the producer of ‘Jigra’, Karan Johar and actress-director Divya Khossla, and of course the underwhelming performance of ‘Jigra’ at the box-office.
-
It is not Reliance but Adar Poonawalla's Serene Productions that has acquired a 50% stake in Karan Johar’s Dharma. On Monday, October 21, Dharma and Serene Entertainment issued a joint statement announcing that Serene Productions will invest INR 1,000 crore into Dharma Productions and Dharmatic Entertainment, India’s leading production house.
-
An agreement has been signed between Bharat Biotech International Limited (BBIL) and BBio wherein BBIL will procure drug substances for the production of OPV to be supplied within India and globally.
-
New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on Sunday wooed Elon Musk to invest in India to manufacture Tesla electric cars, saying it will be the best investment he would have ever made. Musk, who has made a successful USD 44 billion acquisition bid for Twitter, had in the past asked India […]
-
Mumbai: The Pune-based Serum Institute of India (SII) will launch Covavax — its vaccine for children aged above 3 years — in the next six months, SII CEO Adar Poonawalla said here on Tuesday. Covavax is currently under trial and has shown excellent results down to the age of 3 years, Poonawalla said while addressing […]
-
"Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune," he shared in a tweet on Friday.
-
As per BSE block deal data, Poonawalla sold 31,57,034 scrips he held in the firm at a price of Rs 373.85 per share.
-
India rolled out the third phase of its COVID-19 vaccination drive for those in the age group of 18-45 years on Saturday.
-
Amaravati: The Andhra Pradesh government on Saturday placed an order for purchase of 4.08 crore doses each of Covaxin and Covishield for vaccinating 2.04 crore people in the 18-45 age group from May 1. Government Principal Secretary (Covid Management and Vaccination) Muddada Ravichandra wrote letters to Bharat Biotech MD Krishna Yella and Serum Institute of […]
-
Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India. It has been tested against African and UK variants of COVID19 and has an overall efficacy of 89 per cent.
-
The MFI services around 1,87,500 customers across 63 branches spread over 4 states, aggregating a loan portfolio of around Rs 400 crore.
-
Covishield is the brand name for the AstraZeneca-Oxford University COVID-19 vaccine.
-
The city-based firm has already produced Covishield vaccine, co-developed by the University of Oxford and British-Swedish company AstraZeneca.
-
The Drugs Controller General of India (DCGI) on Sunday approved Oxford COVID-19 vaccine Covishield
-
Poonawalla joined the Serum Institute of India in 2001 and became the CEO of Serum Institute with complete control of the day-to-day operations of the company in 2011.
-
The Oxford-AstraZeneca vaccine is being made in partnership with Serum Institute.
